NO976047L - Triazol antisoppmiddel - Google Patents

Triazol antisoppmiddel

Info

Publication number
NO976047L
NO976047L NO976047A NO976047A NO976047L NO 976047 L NO976047 L NO 976047L NO 976047 A NO976047 A NO 976047A NO 976047 A NO976047 A NO 976047A NO 976047 L NO976047 L NO 976047L
Authority
NO
Norway
Prior art keywords
het
alkyl
group
substituents
alkoxy
Prior art date
Application number
NO976047A
Other languages
English (en)
Norwegian (no)
Other versions
NO976047D0 (no
Inventor
Andrew Simon Bell
Michael Jonathan Fray
Allan Patrick Marchington
Kenneth Richardson
Peter Thomas Stephenson
Peter John Whittle
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO976047D0 publication Critical patent/NO976047D0/no
Publication of NO976047L publication Critical patent/NO976047L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO976047A 1995-06-26 1997-12-22 Triazol antisoppmiddel NO976047L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9512961.5A GB9512961D0 (en) 1995-06-26 1995-06-26 Antifungal agents
PCT/EP1996/002470 WO1997001552A1 (en) 1995-06-26 1996-06-05 Triazole antifungal agents

Publications (2)

Publication Number Publication Date
NO976047D0 NO976047D0 (no) 1997-12-22
NO976047L true NO976047L (no) 1998-02-25

Family

ID=10776672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO976047A NO976047L (no) 1995-06-26 1997-12-22 Triazol antisoppmiddel

Country Status (25)

Country Link
US (1) US6015825A (de)
EP (1) EP0835252B1 (de)
JP (1) JP3105926B2 (de)
KR (1) KR19990028390A (de)
AR (1) AR002761A1 (de)
AT (1) ATE246186T1 (de)
AU (1) AU697405B2 (de)
BR (1) BR9609298A (de)
CA (1) CA2224983C (de)
CO (1) CO4480719A1 (de)
CZ (1) CZ415597A3 (de)
DE (1) DE69629300T2 (de)
DK (1) DK0835252T3 (de)
ES (1) ES2202453T3 (de)
GB (1) GB9512961D0 (de)
HU (1) HUP9803022A2 (de)
IL (1) IL118698A0 (de)
NO (1) NO976047L (de)
NZ (1) NZ311651A (de)
PE (1) PE4698A1 (de)
PL (1) PL324336A1 (de)
PT (1) PT835252E (de)
TR (1) TR199701699T1 (de)
WO (1) WO1997001552A1 (de)
ZA (1) ZA965365B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
KR100572996B1 (ko) * 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
EP2228369A1 (de) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazolderivate als modulatoren von proteinkinase
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
KR100738228B1 (ko) * 2006-02-22 2007-07-12 한국화학연구원 아졸계 항균제 화합물 및 그의 제조방법
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
SI2563771T1 (sl) * 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
WO2012123952A1 (en) * 2011-03-15 2012-09-20 Fdc Limited Enantiomers of fluconazole analogues containing thieno-[2,3-d]pyrimidin-4(3h)-one moiety as antifungal agents
KR20140040235A (ko) 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
JP2014523880A (ja) 2011-06-23 2014-09-18 ヴィアメット ファーマスーティカルズ,インコーポレイテッド 金属酵素化合物
IN2014DN06792A (de) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
TWI646088B (zh) * 2012-03-16 2019-01-01 維愛美製藥公司 金屬酶抑制劑化合物
WO2013144224A1 (en) * 2012-03-27 2013-10-03 Syngenta Participations Ag Acetylenic microbiocides
WO2015037013A1 (en) * 2013-09-13 2015-03-19 Suven Life Sciences Limited Process for the large scale production of 1h- [1,2,3]triazole and its intermediate 1-benzyl-1h-[1,2,3] triazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729523A (en) * 1984-06-11 1988-03-08 Kabushiki Kaisha Tokai-Rika-Denki-Seisakusho Locking mechanism for webbing retractor
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9107055D0 (en) * 1991-04-04 1991-05-22 Pfizer Ltd Triazole antifungal agents
GB9121456D0 (en) * 1991-10-10 1991-11-27 Pfizer Ltd Triazole antifungal agents
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
CA2145458A1 (en) * 1994-03-28 1995-09-29 Hiroki Kodama Triazole compound and production process and use thereof

Also Published As

Publication number Publication date
CO4480719A1 (es) 1997-07-09
AU697405B2 (en) 1998-10-08
PT835252E (pt) 2003-11-28
CZ415597A3 (cs) 1998-11-11
JPH10506652A (ja) 1998-06-30
GB9512961D0 (en) 1995-08-30
WO1997001552A1 (en) 1997-01-16
KR19990028390A (ko) 1999-04-15
JP3105926B2 (ja) 2000-11-06
IL118698A0 (en) 1996-10-16
HUP9803022A2 (hu) 1999-10-28
NO976047D0 (no) 1997-12-22
US6015825A (en) 2000-01-18
NZ311651A (en) 1999-09-29
EP0835252B1 (de) 2003-07-30
DE69629300D1 (de) 2003-09-04
ZA965365B (en) 1997-12-29
PL324336A1 (en) 1998-05-25
CA2224983A1 (en) 1997-01-16
TR199701699T1 (xx) 1998-06-22
ES2202453T3 (es) 2004-04-01
EP0835252A1 (de) 1998-04-15
ATE246186T1 (de) 2003-08-15
DE69629300T2 (de) 2004-03-04
AU6301096A (en) 1997-01-30
PE4698A1 (es) 1998-03-03
BR9609298A (pt) 1999-05-18
AR002761A1 (es) 1998-04-29
DK0835252T3 (da) 2003-10-27
MX9800046A (es) 1998-08-30
CA2224983C (en) 2003-04-08

Similar Documents

Publication Publication Date Title
NO924522L (no) Optisk aktive azolforbindelser, deres fremstilling og anvendelse
DE69413238D1 (en) Indolderivate als thromboxane a2 antagonisten
NO20064366L (no) Tiazolderivat
CA2396738A1 (en) Thiazole derivatives as active superoxide radical inhibitors
YU25299A (sh) Paraziticidni pirazoli
DK0984955T3 (da) Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og 1-oxo-isoindoliner og fremgangsmåde til reduktion af TNF-alpha-niveauer
CA2319005A1 (en) 2-pyridylmethylamine derivatives useful as fungicides
NO20063549L (no) (3-okso-3,4-dihydro-quinoksalin-2-yl-amino)-Benzamidderivater og relatert forbindelse som glykogenfosforylaseinhibitorer for behandling av diabetes og fedme
DK1022272T3 (da) Substituerede, fusionerede, heterocykliske forbindelser
TWI265164B (en) 3-substituted-4-pyrimidone derivatives
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
GR3006247T3 (de)
NO975987L (no) 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater
NO20053133L (no) Kjemiske forbindelser.
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
CA2143323A1 (en) Herbicidal 2-[(Heterocyclic-Phenoxymethyl)Phenoxy] -Alkanoates
BG100815A (en) Insecticidal n-(substituted arylmethyl)-4[bis(substituted phenyl)methyl] piperidines
MX9605434A (es) Derivados de di-oxadiazol como agentes antihiperglicemicos.
CO4480719A1 (es) Agentes antifungicos derivados del triazol
CA2355243A1 (en) Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives
GB2311780A (en) Piperazine-2,5-dione derivatives as modulators of multidrug resistance
ES8101071A1 (es) Procedimiento para preparar nuevos derivados de (piridil-2)-2-tetrahidrotiofeno
ES8502091A1 (es) Procedimiento para preparar derivados de bencilcarbamoilpiridina.
GR3035029T3 (en) Triazole antifungal agents
NO983656L (no) Heterocyklyl-ergolinderivater som 5-HT1A reseptorligander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application